Solaraze
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Interest is increasing in the use of sequential or combined therapeutic modalities for spot or area treatment of actinic…
ABSTRACTPurposeThe purpose of this study was to determine if non-specific COX inhibition could extend pore lifetime in hairless…
Rx Only FOR DERMATOLOGIC USE ONLY. NOT FOR OPHTHALMIC USE. DESCRIPTION Solaraze (diclofenac sodium) Gel, 3%, contains the active…
Epidemiological evidence has identified a 3-fold increase in squamous cell skin cancer incidence in men compared to women. The…
Solaraze® gel (Shire Deutschland GmbH & Co. KG, Cologne, Germany) containing 3% diclofenac has been licensed in 2001 as a topical…
Topical treatment with 3% diclofenac in 2.5% hyaluronic acid (Solaraze) has been extensively documented for the treatment of…
A clearance rate of all occurrences > or = 75% for actinic keratoses (AK) lesions is an accepted efficacy endpoint for topical…
The treatment of actinic keratoses (AKs) provides an important opportunity to prevent the development of squamous cell carcinoma…